Clinical Research Directory

Inclusion criteria 1. Biopsy confirmed diagnosis of IgAN. 2. Age ≥18 years at index date. 3. Eligible for treatment with iptacopan or atrasentan as per approved drug label and local regulations at the discretion of treating physician. 4. Able to provide written consent for participation. a. Patients who withdraw their consent will be censored on this date; all aggregated and anonymised data collected up to that date will be included in a centralised IgNITE data platform. Exclusion criteria 1. Use of investigational drugs during the study, OR within 3 months before index date, OR within 5 half-lives of investigational drug before index date, OR until the expected pharmacodynamic effect has returned to baseline, whichever is longer. 2. Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored study (NIS or interventional) with iptacopan/atrasentan. 3. Known hypersensitivity or contraindications to iptacopan, atrasentan, or their excipients, as documented in the patient's medical records. 4. Presence of significant comorbidities or conditions that may impact the interpretation of the study results or the patient's ability to participate in the study at the discretion of treating physician. 5. Pregnancy or other contraindications for iptacopan and/or atrasentan 6. Insufficient medical records available for the baseline and follow-up periods.